Literature DB >> 17435115

X-linked clonality testing: interpretation and limitations.

George L Chen1, Josef T Prchal.   

Abstract

Clonality often defines the diseased state in hematology. Clonal cells are genetically homogenous and derived from the same precursor; their detection is based on genotype or phenotype. Genotypic clonality relies on somatic mutations to mark the clonal population. Phenotypic clonality identifies the clonal population by the expression pattern of surrogate genes that track the clonal process. The most commonly used phenotypic clonality methods are based on the X-chromosome inactivation principle. Clonality detection based on X-chromosome inactivation patterns (XCIP) requires discrimination of the active from the inactive X chromosome and differentiation of each X chromosome's parental origin. Detection methods are based on detection of X-chromosome sequence polymorphisms identified by protein isoforms, transcribed mRNA, and methylation status. Errors in interpreting clonality tests arise from stochastic, genetic, and cell selection pressures on the mechanism of X inactivation. Progressive X-chromosome skewing has recently been suggested by XCIP clonality studies in aging hematopoietic cells. This has led to new insights into the pathophysiology of X-linked and autoimmune disorders. Other research applications include combining XCIP clonality testing with genetic clonality testing to identify clonal populations with yet-to-be-discovered genetic changes.

Entities:  

Mesh:

Year:  2007        PMID: 17435115      PMCID: PMC1975831          DOI: 10.1182/blood-2006-09-018655

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  85 in total

1.  The normal human female as a mosaic of X-chromosome activity: studies using the gene for C-6-PD-deficiency as a marker.

Authors:  E BEUTLER; M YEH; V F FAIRBANKS
Journal:  Proc Natl Acad Sci U S A       Date:  1962-01-15       Impact factor: 11.205

2.  Allocycly of the X-chromosome in tumors and normal tissues.

Authors:  S OHNO; T S HAUSCHKA
Journal:  Cancer Res       Date:  1960-05       Impact factor: 12.701

3.  Clinical implications of the JAK2 V617F mutation in essential thrombocythemia.

Authors:  E Antonioli; P Guglielmelli; A Pancrazzi; C Bogani; M Verrucci; V Ponziani; G Longo; A Bosi; A M Vannucchi
Journal:  Leukemia       Date:  2005-10       Impact factor: 11.528

4.  Transient homologous chromosome pairing marks the onset of X inactivation.

Authors:  Na Xu; Chia-Lun Tsai; Jeannie T Lee
Journal:  Science       Date:  2006-01-19       Impact factor: 47.728

5.  Transient colocalization of X-inactivation centres accompanies the initiation of X inactivation.

Authors:  Christian P Bacher; Michèle Guggiari; Benedikt Brors; Sandrine Augui; Philippe Clerc; Philip Avner; Roland Eils; Edith Heard
Journal:  Nat Cell Biol       Date:  2006-01-24       Impact factor: 28.824

6.  X-inactivation-based clonality analysis and quantitative JAK2V617F assessment reveal a strong association between clonality and JAK2V617F in PV but not ET/MMM, and identifies a subset of JAK2V617F-negative ET and MMM patients with clonal hematopoiesis.

Authors:  Ross L Levine; Claude Belisle; Martha Wadleigh; David Zahrieh; Stephanie Lee; Pierre Chagnon; D Gary Gilliland; Lambert Busque
Journal:  Blood       Date:  2006-01-24       Impact factor: 22.113

7.  Identification of an acquired JAK2 mutation in polycythemia vera.

Authors:  Runxiang Zhao; Shu Xing; Zhe Li; Xueqi Fu; Qingshan Li; Sanford B Krantz; Zhizhuang Joe Zhao
Journal:  J Biol Chem       Date:  2005-04-29       Impact factor: 5.157

8.  X chromosome monosomy: a common mechanism for autoimmune diseases.

Authors:  Pietro Invernizzi; Monica Miozzo; Carlo Selmi; Luca Persani; Pier Maria Battezzati; Massimo Zuin; Simona Lucchi; Pier Luigi Meroni; Bianca Marasini; Silvana Zeni; Mitchell Watnik; Francesca R Grati; Giuseppe Simoni; M Eric Gershwin; Mauro Podda
Journal:  J Immunol       Date:  2005-07-01       Impact factor: 5.422

9.  JAK2 mutation 1849G>T is rare in acute leukemias but can be found in CMML, Philadelphia chromosome-negative CML, and megakaryocytic leukemia.

Authors:  Jaroslav Jelinek; Yasuhiro Oki; Vazganush Gharibyan; Carlos Bueso-Ramos; Josef T Prchal; Srdan Verstovsek; Miloslav Beran; Elihu Estey; Hagop M Kantarjian; Jean-Pierre J Issa
Journal:  Blood       Date:  2005-07-21       Impact factor: 22.113

10.  High frequency of skewed X-chromosome inactivation in females with autoimmune thyroid disease: a possible explanation for the female predisposition to thyroid autoimmunity.

Authors:  Thomas Heiberg Brix; Gun Peggy S Knudsen; Marianne Kristiansen; Kirsten Ohm Kyvik; Karen Helene Orstavik; Laszlo Hegedüs
Journal:  J Clin Endocrinol Metab       Date:  2005-08-16       Impact factor: 5.958

View more
  18 in total

1.  Extent of hematopoietic involvement by TET2 mutations in JAK2V⁶¹⁷F polycythemia vera.

Authors:  Sabina I Swierczek; Donghoon Yoon; Christine Bellanné-Chantelot; Soo Jin Kim; Cécile Saint-Martin; Francois Delhommeau; Albert Najman; Josef T Prchal
Journal:  Haematologica       Date:  2011-01-27       Impact factor: 9.941

Review 2.  Acute myeloid leukemia stem cells and CD33-targeted immunotherapy.

Authors:  Roland B Walter; Frederick R Appelbaum; Elihu H Estey; Irwin D Bernstein
Journal:  Blood       Date:  2012-01-27       Impact factor: 22.113

3.  Methylation of AR locus does not always reflect X chromosome inactivation state.

Authors:  Sabina I Swierczek; Lucie Piterkova; Jaroslav Jelinek; Neeraj Agarwal; Sue Hammoud; Andrew Wilson; Kimberly Hickman; Charles J Parker; Bradley R Cairns; Bradley Cairns; Josef T Prchal
Journal:  Blood       Date:  2012-01-27       Impact factor: 22.113

4.  Spontaneous abrogation of the G₂DNA damage checkpoint has clinical benefits but promotes leukemogenesis in Fanconi anemia patients.

Authors:  Raphael Ceccaldi; Delphine Briot; Jérôme Larghero; Nadia Vasquez; Catherine Dubois d'Enghien; Delphine Chamousset; Maria-Elena Noguera; Quinten Waisfisz; Olivier Hermine; Corinne Pondarre; Thierry Leblanc; Eliane Gluckman; Hans Joenje; Dominique Stoppa-Lyonnet; Gérard Socié; Jean Soulier
Journal:  J Clin Invest       Date:  2010-12-22       Impact factor: 14.808

5.  Why the disorder induced by GATA1 Arg216Gln mutation should be called "X-linked thrombocytopenia with thalassemia" rather than "X-linked gray platelet syndrome".

Authors:  Carlo L Balduini; Erica De Candia; Anna Savoia
Journal:  Blood       Date:  2007-10-01       Impact factor: 22.113

6.  Hematopoiesis is not clonal in healthy elderly women.

Authors:  Sabina I Swierczek; Neeraj Agarwal; Roberto H Nussenzveig; Gerald Rothstein; Andrew Wilson; Andrew Artz; Josef T Prchal
Journal:  Blood       Date:  2008-07-18       Impact factor: 22.113

Review 7.  Pathogenesis of chagas' disease: parasite persistence and autoimmunity.

Authors:  Antonio R L Teixeira; Mariana M Hecht; Maria C Guimaro; Alessandro O Sousa; Nadjar Nitz
Journal:  Clin Microbiol Rev       Date:  2011-07       Impact factor: 26.132

8.  Clonal patterns of X-chromosome inactivation in peripheral blood cells of female patients with chronic idiopathic neutropenia.

Authors:  Semeli Mastrodemou; Vasilios Vazgiourakis; Maria Velegraki; Konstantia Pavlaki; George N Goulielmos; Helen A Papadaki
Journal:  Haematologica       Date:  2012-08-08       Impact factor: 9.941

9.  A sensitive detection method for MPLW515L or MPLW515K mutation in chronic myeloproliferative disorders with locked nucleic acid-modified probes and real-time polymerase chain reaction.

Authors:  Alessandro Pancrazzi; Paola Guglielmelli; Vanessa Ponziani; Gaetano Bergamaschi; Alberto Bosi; Giovanni Barosi; Alessandro M Vannucchi
Journal:  J Mol Diagn       Date:  2008-07-31       Impact factor: 5.568

10.  The clinical utility of molecular diagnostic testing for primary immune deficiency disorders: a case based review.

Authors:  Rohan Ameratunga; See-Tarn Woon; Katherine Neas; Donald R Love
Journal:  Allergy Asthma Clin Immunol       Date:  2010-06-08       Impact factor: 3.406

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.